Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting

Sclerostin antibody (romosozumab) was recently approved for clinical use in the United States to treat osteoporosis. We and others have explored Wnt‐based combination therapy to disproportionately improve the anabolic effects of sclerostin inhibition, including cotreatment with sclerostin antibody (...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Roy B, Bullock, Whitney A, Hoggatt, April M, Loots, Gabriela G, Genetos, Damian C, Robling, Alexander G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101614/
https://www.ncbi.nlm.nih.gov/pubmed/33977198
http://dx.doi.org/10.1002/jbm4.10462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101614/
https://www.ncbi.nlm.nih.gov/pubmed/33977198
http://dx.doi.org/10.1002/jbm4.10462

Ejemplares similares